Leveraging Viruses for the Treatment of Viral Diseases and Cancer

Improving Host Fitness by Combinations of Virus and Host Genes

Tibor Bakacs (Herausgeber)

Buch | Softcover

200 Seiten

2025
Academic Press Inc (Verlag)
978-0-443-29164-7 (ISBN)

Infos

Leveraging Viruses for the Treatment of Viral Diseases and Cancer: Improving Host Fitness by Combinations of Virus and Host Genes gives a comprehensive overview about the impact of using naturally or intentionally attenuated viruses, which are apathogenic to people, to control viral diseases and cancer. The book examines the potential of exploiting, developing, and using of apathogenic viruses as therapeutic tool against viral diseases and cancer. It specifically covers the COVID-19 pandemic and the need for a post-Infection Plan B to combat SARS-CoV-2 infections as gaps in testing and vaccination create the perfect conditions for a new variant of concern to emerge which could cause significant mortality thus demonstrating a need for further research for inexpensive and effective therapies. More generally, the book also provides specific examples of the use of apathogenic viruses to treat other infectious diseases. It discusses the process of manufacturing viral therapies and how infectious disease treatments can be repurposed to improve other therapies like for cancer. With contribution from an international group of contributors, Leveraging Viruses for the Treatment of Viral Diseases and Cancer is useful references for those engages in study and development of infectious diseases and ways to combat them.

Autor

Dr. Tibor Bakacs has 40 years of experience in scientific research. His current interests are (i) viral superinfection treatment (SIT) of hepatitis B and C virus infected patients with unmet needs; (ii) oncolytic Newcastle Disease virus (NDV) therapy of advanced cancer; (iii) therapeutic application of autoimmune T-cells, which are induced by an off-label low-dose immune checkpoint blockade in advanced cancer. Formerly, he was the Head of Immunology at the Hungarian National Institute of Oncology. He spent longer periods abroad, at the Karolinska Institute in Stockholm, Sweden, Christie Hospital in Manchester, UK and the National Cancer Institute (NCI/NIH) in the USA. Currently, he is the Chief Scientific Officer of Superinfection, Pret Therapeutics Ltd, and Lodoco Clinical Ltd. He is also a consultant at the Department of Probability, Alfred Renyi Institute of Mathematics. Dr. Bakacs authored 75 scientific papers and has two patents.

Inhalt

1. The Impact of Viral Creativity on the Evolution of Cellular Genes
2. Our Antiviral Defense Comes from Viruses
3. Exploiting Viral Interference for Therapy
4. Fighting Fire with Fire: Vaccine Viruses to Control Viral Diseases
5. A Post-Infection Plan B to Complement COVID-19 Vaccination
6. Live Viral Vaccines Can Temporarily Protect Against COVID-19
7. Reduced Mortality Among HIV Infected Patients Coinfected with a Common Human Virus
8. Breakthrough Infection can be Achieved in the Presence of Neutralizing Antibodies by Multiple Administrations of Viruses
9. Safety and Regulatory Hurdles of Viral Therapy
10. Simplicity and Affordability of Manufacturing the Infectious Bursal Disease Virus (IBDV)
11. Three Out Of Four New Diseases are Zoonotic: Neglected Pandemic Threats in the United States
12. The Impact of Conventional Acyclovir Complemented with Immunostimulatory IBDV on the Crusting Time of Shingles
13. Combination of IBDV With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus Infections
14. Need for Further Research Providing Cheap and Effective Therapies for COVID-19
15. Repurposing Infectious Diseases Vaccines to Improve Cancer Therapy

Produkt-Details

• Erscheint lt. Verlag: 1.7.2025
• Verlagsort: San Diego
• Sprache: englisch
• Maße: 152 x 229 mm
• Themenwelt: Naturwissenschaften ► Biologie ► Mikrobiologie / Immunologie
• ISBN-10: 0-443-29164-0 / 0443291640
• ISBN-13: 978-0-443-29164-7 / 9780443291647
• Zustand: Neuware